Drug intelligence / Profile preview

Li-Ankang

Development stage: Preclinical
Modality: Small Molecules

Overview

Li-Ankang is a hemodialysis concentrated powder designed for use in preparing dialysate for patients undergoing hemodialysis. It is being investigated in a clinical study for its effect on the long-term prognosis of hemodialysis patients, particularly concerning complications of hemodialysis. The product functions by contributing to the removal of metabolic waste products and toxins from the blood, while also helping to maintain electrolyte and acid-base balance, thereby mimicking the natural filtration processes of healthy kidneys.

Brand names: Beijing Li'ankang Hemodialysis Concentrated Powder
Other names: 北京利安康血液透析浓缩粉

Targets

ClC (CLC chloride channel family)

Beyond the preview

Go deeper on Li-Ankang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Li-Ankang.

Explore the full profile